Biogen
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees7,605
Employees7,605
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees7,605
Employees7,605
BIIB Key Statistics
Market cap19.22B
Market cap19.22B
Price-Earnings ratio12.59
Price-Earnings ratio12.59
Dividend yield—
Dividend yield—
Average volume1.58M
Average volume1.58M
High today$131.19
High today$131.19
Low today$127.53
Low today$127.53
Open price$128.04
Open price$128.04
Volume204.70K
Volume204.70K
52 Week high$238.00
52 Week high$238.00
52 Week low$110.04
52 Week low$110.04
BIIB News
Simply Wall St 2d
Biogen (NasdaqGS:BIIB) Partners With City Therapeutics in US$1 Billion RNAi Therapy Dealrecently announced a collaboration with City Therapeutics, Inc. to develop RNAi therapies for central nervous system diseases, contributing to a 6% share price...
Seeking Alpha 2d
Biogen and City Therapeutics partner to develop RNAi therapiesBiogen (NASDAQ:BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ((RNAi)) therapies targeting serious diseases. Under the ag...
Analyst ratings
51%
of 37 ratingsBuy
48.6%
Hold
51.4%
Sell
0%
People also own
Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.